US Edition
Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD
Summary by ajmc.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD
Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
